Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMAAP-AF: Educational Program and Medication Adherence to DOACs in Non-valvular Atrial Fibrillation
jRCTs031180142Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of edoxaban and apixaban in nonvalvular atrial fibrillation (NVAF) (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Started May 2018; status: completed.
02
Drugs
edoxabanapixaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on jRCTs031180142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180142.